HRP20180361T1 - Sustav za isporuku lijeka za liječenje ili dijagnozu neuroloških poremećaja - Google Patents
Sustav za isporuku lijeka za liječenje ili dijagnozu neuroloških poremećaja Download PDFInfo
- Publication number
- HRP20180361T1 HRP20180361T1 HRP20180361TT HRP20180361T HRP20180361T1 HR P20180361 T1 HRP20180361 T1 HR P20180361T1 HR P20180361T T HRP20180361T T HR P20180361TT HR P20180361 T HRP20180361 T HR P20180361T HR P20180361 T1 HRP20180361 T1 HR P20180361T1
- Authority
- HR
- Croatia
- Prior art keywords
- virus
- vlp
- particle
- disorder
- pain
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title claims 8
- 238000003745 diagnosis Methods 0.000 title claims 3
- 208000025966 Neurological disease Diseases 0.000 title 1
- 238000012377 drug delivery Methods 0.000 title 1
- 239000002245 particle Substances 0.000 claims 25
- 208000002193 Pain Diseases 0.000 claims 8
- 101710108545 Viral protein 1 Proteins 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 210000003169 central nervous system Anatomy 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- 101000714457 Chaetoceros protobacilladnavirus 2 Capsid protein Proteins 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 201000003631 narcolepsy Diseases 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 4
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 4
- 241000701460 JC polyomavirus Species 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 206010054196 Affect lability Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 102000014461 Ataxins Human genes 0.000 claims 2
- 108010078286 Ataxins Proteins 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010008748 Chorea Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 206010013642 Drooling Diseases 0.000 claims 2
- 208000027776 Extrapyramidal disease Diseases 0.000 claims 2
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims 2
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims 2
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 2
- 208000002033 Myoclonus Diseases 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 108010071690 Prealbumin Proteins 0.000 claims 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000018642 Semantic dementia Diseases 0.000 claims 2
- 208000008630 Sialorrhea Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 206010044074 Torticollis Diseases 0.000 claims 2
- 102000009190 Transthyretin Human genes 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 208000012886 Vertigo Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 2
- 208000018300 basal ganglia disease Diseases 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 201000002866 cervical dystonia Diseases 0.000 claims 2
- 208000012601 choreatic disease Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 230000001054 cortical effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 230000005586 smoking cessation Effects 0.000 claims 2
- 208000018198 spasticity Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- -1 thrombolytics Substances 0.000 claims 2
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 231100000889 vertigo Toxicity 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 208000033001 Complex partial seizures Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 1
- 241001505332 Polyomavirus sp. Species 0.000 claims 1
- 208000032140 Sleepiness Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229940005524 anti-dementia drug Drugs 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 229940005530 anxiolytics Drugs 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000003825 glutamate receptor antagonist Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 239000002664 nootropic agent Substances 0.000 claims 1
- 230000001777 nootropic effect Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 230000037321 sleepiness Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
- C12N2710/22042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
- C12N2710/22043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22071—Demonstrated in vivo effect
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (16)
1. Virusu slične čestica (VLP) izveden ljudskog virusa polioma sadrži lijek za primjenu u postupku liječenja terapijom ili metoda dijagnoze in vivo neurološkog poremećaja središnjeg živčanog sustava, pri čemu je neurološki poremećaj odabran iz skupine koja se sastoji od moždanog udara, ovisnosti o alkoholu, Alzheimerovu bolest, anksioznost, poremećaj pažnje hiperaktivnost, biipolarni poremećaj, kancerogenu bol, cerebralna ishemija, cervikalna distonija, Chorea povezana s Hungtigtonovom bolesti, kronični bol, kronična teška bol, kognitivni poremećaj, kortikalni mioklonus, depresija, dijabetička neuropatska bol, emocionalna labilnost, epilepsija, prekomjerna pospanost povezana s narkolepsijom, fragilnosg X sindroma, Friedrichova ataksija, nesanica, Lennox-Gastautov sindrom, veći poremećaji depresije i anksioznosti, manične epizode povezane s bipolarnim poremećajem, oštećenje memorije, migrena, blago kognitivno oštećenje, umjerena do ozbiljna bol, bolesti motoričkih neurona, multipla skleroza, bol mišićno-koštane srži, narkolepsija, neuropatska bol, ovisnost o nikotinu, opsesivno kompulzivni poremećaj, bol u osteoartritisu, Parkinsonova bolest, pedrijatrijsko slinjenje, postoperativni bol, predmenstrualni disforički poremećaj, psihoze, parcijalni epileptični napadi refraktornog kompleksa, shizofrenija, konvulzija, poremećaj spavanja, prestanak pušenja, spastičnost, povreda kičmene moždine, transtiretin porodična amilooidna polineuropatija, traumatska povreda mozga, vertigo, amiotropna lateralna skleroza, spinocerebelarna ataksija tipa I, ekstrapiramidalni poremećaj i poremećaj kretanja, tranzitijalna ishemijska ataka (TIA), progresivna multifokalna leukoencefalopatija (PML), demencija, kao što je Alzheimerova bolest, vaskularna demencija, frontnotemporna demencija prednjeg režnja, semantička demencija i demencija s Lewyevim tijelima.
2. Virusu slična čestica (VLP) za uporabu sukladno patentnom zahtjevu 1, pri čemu je navedena virusu slična čestica (VLP) izvedena iz JC polioma virusa (JCV).
3. Virusu slična čestica (VLP) za uporabu sukladno patentnim zahtjevima 1 ili 2, pri čemu je neurološki poremećaj Alzheimerova bolest.
4. Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, gdje je neurološki poremećaj Parkinsonova bolest.
5. Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, gdje je neurološki poremećaj multipla skleroza.
6. Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, pri čemu pomenuti VLP ulazi u navedenu stanicu središnjeg živčanog sustava (CNS) zajedno s lijekom koji je enkapsuliran pomoću virusu slične čestice (VLP).
7. Virusu slična čestica (VLP) za uporabu sukladno barem jednim od gore navedenih patentnih zahtjeva, pri čemu virusu slična čestica (VLP) koja sadrži lijek prelazi fiziološki netaknutu krvno moždanu barijeru.
8. Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, pri čemu po sastavu virusu slične čestice (VLP) čine proteini virusnog proteina 1 (VP1) od JC virusa.
9. Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gornjih patentnih zahtjeva, pri čemu je virusu slična čestica (VLP) primenjena putem koja omogućuje sustavni učinak lijeka.
10. Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, pri čemu se virusu slična čestica (VLP) primjenjuje oralno, parenteralno ili intravenozno.
11. Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, pri čemu se virusu slična čestica (VLP) primenjena intravenozno.
12. Virusu slična čestica za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, pri čemu virusu slična čestica (VLP) sadrži virusni protein 1 (VP1) i/ili virusnog proteina 2 (VP2), pri čemu taj virusni protein 1 (VP1) sadrži aminokiselinsku sekvencu koja je najmanje 80% identična aminokiselinskoj sekvenci prema SEK ID BR: 1 duž cijele njene dužine i/ili pri čemu virusni protein 2 (VP2) sadrži aminokiselinsku sekvencu koja je najmanje 80% identična aminokiselinskoj sekvenci prema SEK ID BR: 3 duž cijele njene dužine.
13. Virusu slična čestica (VLP) za uporabu sukladno bilo kojem od gore navedenih patentnih zahtjeva, pri čemu je lijek odabran iz skupine koja se sastoji od CNS aktivnog spoja, agensa koji se može detektirati kao što je radionuklid, protein, peptid i nukleinska kiselina, posebno odabrana skupina koja se sastoji od nukleinske kiseline koje kodiraju željeni protein kao što je mRNK, cDNK, plazmid ili vektor; inhibirajuće nukleinske kiseline kao što je siRNK ili miRNK; i nukleinske kiseline koje imaju katalitičku aktivnost kao što je ribozim.
14. Virusu slična čestica (VLP) za uporabu sukladno patentnom zahtjevu 13, pri čemu je lijek odabran iz skupine koja sadrži monoklonalna antitijela, antipsihotičke lijekove, analgetičke lijekove, trombolitike, antidepresive, imunomodulatore, imunosupresive, inhibitore acetilkolinesteraze, antagoniste ili modulatore glutamatnog receptora, kao što su antagonisti NMDA receptora, psihostimulansi, lijekovi protiv demencije, anksiolitici, nootropici, pojačivači metabolizma, modulatori metabolizma, neuroprotektivnii lijekovi, i antiepileptici.
15. Farmaceutski pripravak namijenjen uporabi u postupku liječenja terapijom ili metodom in vivo dijagnosticiranjaze neurološkog poremećaja središnjeg živčanog sustava, pri čemu farmaceutski pripravak sadrži virusu sličnu česticu (VLP) prema bilo kojem od gore navedenih patentnih zahtjeva pri čemu najmanje 1%, poželjno najmanje 15%, još poželjnije najmanje 50%, u osobito poželjno 95% ukupna količina supstance lijeka (teret) je potpuno enkapsulirana u opni virusu slične čestice (VLP) i pri čemu je neurološki poremećaj odabran iz skupine koja obuhvaća moždani udar, ovisnost o alkoholu, Alzheimerovu bolest, anksioznost, hiperkineički poremećaj, bipolarni poremećaj, kancerogenu bol, cerebralnu ishemiju, cervikalnu distoniju, Chorea povezana s Huntigntonovom bolesti, kronični bol, kroničnu ozbiljnu bol, kognitivni poremećaj, kortikalni mioklonus, depresija, dijabetesni neuropatski bol, emocionalna labilnost, epilepsija, prekomjerno spavanje povezano s narkolepsijom, fragilnosg X sindroma, Friedrichova ataksija, nesanica, Lennox-Gastautov sindrom, veći poremećaji depresije i anksioznosti, manične epizode povezane s bipolarnim poremećajem, oštećenje memorije, migrena, blago kognitivno oštećenje, umjerena do ozbiljna bol, bolesti motoričkih neurona, multipla skleroza, bol mišićno-koštane srži, narkolepsija, neuropatska bol, ovisnost o nikotinu, opsesivno kompulzivni poremećaj, bol u osteoartritisu, Parkinsonova bolest, pedijatrijsko slinjenje, postoperativni bol, predmenstrualni disforički poremećaj, psihoze, parcijalni epileptični napadi refraktornog kompleksa, shizofrenija, konvulzija, poremećaj spavanja, prestanak pušenja, spastičnost, povreda kičmene moždine, transtiretin porodična amilooidna polineuropatija, traumatska povreda mozga, vertigo, amiotropna lateralna skleroza, spinocerebelarna ataksija tipa I, ekstrapiramidalni poremećaj i poremećaj kretanja, tranzitijalna ishemijska ataka (TIA), progresivna multifokalna leukoencefalopatija (PML), demencija, kao što je Alzheimerova bolest, vaskularna demencija, frontnotemporna demencija prednjeg režnja, semantička demencija i demencija s Lewyevim tijelima.
16. Farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 15 pri čemu virusu slične čestice nisu agregirane.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/000656 WO2013131644A1 (en) | 2012-03-06 | 2013-03-06 | A novel drug delivery system based on jcv-vlp |
| EP13001491.3A EP2774991B1 (en) | 2013-03-06 | 2013-03-22 | Drug delivery system for use in the treatment or diagnosis of neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180361T1 true HRP20180361T1 (hr) | 2018-04-20 |
Family
ID=47915420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180361TT HRP20180361T1 (hr) | 2013-03-06 | 2018-02-28 | Sustav za isporuku lijeka za liječenje ili dijagnozu neuroloških poremećaja |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP3312283A1 (hr) |
| CY (1) | CY1120278T1 (hr) |
| HR (1) | HRP20180361T1 (hr) |
| LT (1) | LT2774991T (hr) |
| NO (1) | NO2774991T3 (hr) |
| PL (1) | PL2774991T3 (hr) |
| SI (1) | SI2774991T1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3031820A1 (en) | 2014-12-08 | 2016-06-15 | Life Science Inkubator | JC Polyomavirus VLP (virus-like particle) with a targeting peptide |
| EP3031821A1 (en) * | 2014-12-08 | 2016-06-15 | Life Science Inkubator | polyomavirus VLPs with a fusion protein |
| RU2682966C1 (ru) * | 2018-03-20 | 2019-03-25 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Комбинации буспирона для лечения головокружения |
| CN111323527B (zh) * | 2018-12-13 | 2022-12-02 | 湖南德米特仪器有限公司 | 一种用复合二维液相色谱同时测定多种精神药物的方法 |
| CN112137994B (zh) * | 2020-09-15 | 2022-10-14 | 中山大学 | 小分子化合物在制备抗丝状病毒药物中的应用 |
| CN115317614B (zh) * | 2022-10-14 | 2022-12-27 | 暨南大学 | Adk抑制剂在制备治疗脊髓损伤的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19543553B4 (de) | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| DE69821227D1 (de) | 1997-04-26 | 2004-02-26 | Rpms Technology Ltd | Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen |
| DE10131145B4 (de) * | 2001-06-28 | 2005-07-14 | Innovent E.V. | Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen |
| EP2036980A1 (de) | 2007-09-14 | 2009-03-18 | Gruber, Jens | Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel |
| EP2394163B1 (en) * | 2009-02-05 | 2020-08-19 | Biogen MA Inc. | Methods for the detection of jc polyoma virus |
-
2013
- 2013-03-22 NO NO13001491A patent/NO2774991T3/no unknown
- 2013-03-22 SI SI201330957T patent/SI2774991T1/en unknown
- 2013-03-22 LT LTEP13001491.3T patent/LT2774991T/lt unknown
- 2013-03-22 PL PL13001491T patent/PL2774991T3/pl unknown
- 2013-03-22 EP EP17205393.6A patent/EP3312283A1/en not_active Withdrawn
- 2013-03-22 EP EP13001491.3A patent/EP2774991B1/en active Active
-
2018
- 2018-02-28 HR HRP20180361TT patent/HRP20180361T1/hr unknown
- 2018-02-28 CY CY20181100252T patent/CY1120278T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2774991T3 (pl) | 2018-05-30 |
| SI2774991T1 (en) | 2018-04-30 |
| EP3312283A1 (en) | 2018-04-25 |
| CY1120278T1 (el) | 2019-07-10 |
| NO2774991T3 (hr) | 2018-05-05 |
| EP2774991B1 (en) | 2017-12-06 |
| EP2774991A1 (en) | 2014-09-10 |
| LT2774991T (lt) | 2018-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180361T1 (hr) | Sustav za isporuku lijeka za liječenje ili dijagnozu neuroloških poremećaja | |
| Ehrnhoefer et al. | Mouse models of Huntington disease: variations on a theme | |
| Lou et al. | Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases | |
| JP2013135695A5 (hr) | ||
| JP2014520072A5 (hr) | ||
| II Timberlake et al. | Linking unfolded protein response to inflammation and depression: potential pathologic and therapeutic implications | |
| JP2016509061A5 (hr) | ||
| HRP20180221T1 (hr) | Novi sustav prijenosa lijeka zasnovan za jcv-vlp | |
| MX2016000019A (es) | (arnip) gen especifico relacionado con las enfermedades respiratorias, (arnip) que contiene la estructura arn oligo helicoidal, composicion que contiene la misma para prevencion o tratamiento de las enfermedades respiratorias. | |
| NZ700374A (en) | New therapeutic approaches for treating parkinson’s disease | |
| JP2019529489A5 (hr) | ||
| MX2019010577A (es) | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro cognitivo. | |
| WO2019238626A1 (en) | Engineering extracellular vesicles for affinity purification | |
| JP2022525208A (ja) | 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド | |
| CA3133784A1 (en) | Oligonucleotide-based modulation of c9orf72 | |
| Holm et al. | Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases | |
| JP2013518914A5 (hr) | ||
| JP2014516535A5 (hr) | ||
| RU2018134615A (ru) | Применение стволовых клеток, экспрессирующих мезенхимальные и нейрональные маркеры, и их композиций для лечения неврологических заболеваний (варианты) | |
| CA3049197A1 (en) | A drug delivery system comprising virus-like particles from john cunningham virus and methods providing thereof | |
| JP2022529009A (ja) | 神経発生 | |
| WO2019246112A1 (en) | Methods of treating schizophrenia and other neuropsychiatric disorders | |
| US20240065988A1 (en) | Combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders | |
| Martinez et al. | MicroRNAs in mouse and rat models of experimental epilepsy and potential therapeutic targets | |
| US20210340533A1 (en) | Oligonucleotides for tissue specific gene expression modulation |